A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer

A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer

Background The current study was conducted to evaluate the efficacy and safety of pembrolizumab‐mediated programmed cell death protein 1 inhibition plus radiotherapy (RT) in patients with metastatic triple‐negative breast cancer who were unselected for programmed death‐ligand 1 expression. Methods T...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer 2020-02, Vol.126 (4), p.850-860
Hauptverfasser: Ho, Alice Y., Barker, Christopher A., Arnold, Brittany B., Powell, Simon N., Hu, Zishuo I., Gucalp, Ayca, Lebron‐Zapata, Lizza, Wen, Hannah Y., Kallman, Cindy, D'Agnolo, Alessandro, Zhang, Zhigang, Flynn, Jessica, Dunn, Samantha A., McArthur, Heather L.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Apoptosis
Biomarkers
Breast cancer
Cell death
checkpoint blockade
Chemoradiotherapy - adverse effects
Chemoradiotherapy - methods
Clinical trials
Cohort Studies
Dermatitis
Dermatitis - etiology
Evaluation
Fatalities
Fatigue - etiology
Female
Humans
Immune checkpoint
Immunotherapy
Kaplan-Meier Estimate
Ligands
Lymphopenia
Lymphopenia - etiology
Medical prognosis
Metastases
Metastasis
metastatic
Middle Aged
Monoclonal antibodies
Mortality
Oncology
Patients
Pembrolizumab
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Programmed Cell Death 1 Receptor - metabolism
Radiation therapy
radiotherapy (RT)
Radiotherapy - adverse effects
Radiotherapy - methods
Safety
Solid tumors
Survival
Targeted cancer therapy
Terminology
Toxicity
Treatment Outcome
Triple Negative Breast Neoplasms - metabolism
Triple Negative Breast Neoplasms - pathology
Triple Negative Breast Neoplasms - therapy
triple‐negative breast cancer (TNBC)
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Schreiben Sie den ersten Kommentar!
Bitte loggen Sie sich zuerst ein